MEASUREMENT STARTING POINTS
Company Baselines
Sourced facts needed to measure a catalyst from a declared starting point. These records are not earnings summaries, forecasts, impact findings or grades.
Baseline standard
Relevant · every fact connects to a defined measurement question.
Dated · the baseline and each reported period remain visible.
Sourced · each fact links to its primary evidence.
Labeled · reported facts and N-Ledger calculations remain distinct.
PUBLISHED BASELINES
Measurement records
Science · Medicine · KYTX · baseline Oct 23, 2026
Kyverna Therapeutics
Kyverna: Can One Miv-cel Infusion Sustain Function Without Chronic Immunotherapy in Refractory Stiff-Person Syndrome?Prospective October 23, 2026 evidence baseline. KYSA-8 treated 26 adults in an open-label single-arm trial; registry enrollment is 27 and the difference is unexplained. The one-year analysis reported a 49% median within-person reduction in 25-foot walk time and 24/26 off chronic SPS immunotherapy. The rolling BLA is incomplete, FDA acceptance and action dates are unknown, and there are no commercial infusions. Four stars is the author's expected breadth judgment; no outcome grade or Realized Depth is recorded. Terminal review is five years after the actual FDA action date, which is not set.
| Measurement | Starting fact | Why it matters | Evidence |
|---|---|---|---|
| Median within-patient reduction in 25-foot walk time | 46% percentKYSA-8 week 16, n=26 · | Single-arm primary endpoint; not a randomized treatment effect. | Source ↗ |
| Median within-patient reduction in 25-foot walk time | 49% percentKYSA-8 one-year analysis, n=26; July 10, 2026 cutoff · | Within-person follow-up; retained patients and rescue treatment must accompany future comparisons. | Source ↗ |
| Off chronic SPS immunotherapy | 24/26 patientsKYSA-8 one-year analysis; July 10, 2026 cutoff · | Trial observation; symptomatic medication changes and post-approval durability remain unknown. | Source ↗ |
| B-cell reconstitution | 17/26 patientsKYSA-8 one-year analysis; July 10, 2026 cutoff · | Biological follow-up, not proof of clinical durability after B-cell return. | Source ↗ |
Public readers can inspect baseline facts for public research. Individual, Professional, Business and Enterprise clients receive company baselines across their applicable coverage.